Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Luye Pharma to Stage $764 Million IPO in Hong Kong

publication date: Jun 23, 2014
Luye Pharma Group, headquartered in Shanghai, plans to raise as much as $764 million in a Hong Kong IPO next month. The diversified pharma, which was previously listed in Singapore, was taken private in 2012 in a transaction that valued the company at $513 million. The new IPO implies a value of $2.5 billion. The parties that participated in the go-private transactions – three private equity firms, the company’s chairman and the sovereign fund of Singapore – will sell shares in the IPO. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital